Key gene increases incidence of acute myelogenous leukemia | Melphalan and stem cell transplants extend myeloma survival in study | Anticonvulsant drug could stop drug-resistant bacteria from replicating
Web Version
 
 
September 24, 2014
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP|FORWARD|ARCHIVE

Top StorySponsored By
Key gene increases incidence of acute myelogenous leukemia
National University of Singapore scientists found that blocking the Leo1 gene and signaling pathways could be used to treat acute myelogenous leukemia. The study also found the protein PRL-3, which is overexpressed in about 47% of AML cases, is involved in the regulation of ribonucleic acid processes. BioSpectrum Asia (9/23)
Share: LinkedInTwitterFacebookGoogle+Email
When's the last time you visited Immucor's LEARN?
Immucor's Lab Education and Resource Network (LEARN) website continues to grow — with 2 new courses available this month. LEARN offers you the flexibility to take courses at your convenience and provides complimentary CE credits for you and your staff. Visit the LEARN website or contact your local Immucor Blood Bank Business Manager for more information.
Advertisement
 
Science & Health
Melphalan and stem cell transplants extend myeloma survival in study
High-dose melphalan treatment and autologous stem cell transplantation were associated with increased progression-free survival and overall survival in a study of 273 patients with myeloma. The treatment was compared with melphalan, prednisone and lenalidomide in the late-stage study whose findings were reported in The New England Journal of Medicine. Healio (free registration)/HemOnc Today (9/23)
Share: LinkedInTwitterFacebookGoogle+Email
Anticonvulsant drug could stop drug-resistant bacteria from replicating
A study by researchers from McMaster University and the Scripps Research Institute has found that GlaxoSmithKline's anticonvulsant drug lamotrigine can prevent bacteria from making ribosomes. The study, published in the journal eLife, suggests that ribosome inhibitors could lead to a new class of antibiotics. Medical News Today (9/23)
Share: LinkedInTwitterFacebookGoogle+Email
PBM Workshop Highlights Business Case and Business Plan for PBM
A forerunner to the AABB Annual Meeting, the PBM Preconference Workshop: Better Care and Better Patient Outcomes is a full-day workshop that will highlight business cases and the development of business plans around PBM. Expert speakers will discuss clinical and operational considerations for PBM programs. Register today for the PBM Workshop, Friday, October 24.
Advertisement
 
Emerging Trends
Cedars-Sinai scientists test Vital Therapies' bioartificial liver
An artificial liver device designed by Vital Therapies is being tested at Cedars-Sinai Medical Center and 48 other sites as a potential treatment for patients with alcohol-related liver disease. The device called BAL draws blood from the patient using a central venous line and filters the blood using tubes embedded with liver cells. The filtered and treated blood is then returned to the patient through the central line. Healio (free registration) (9/23)
Share: LinkedInTwitterFacebookGoogle+Email
Core Principles in Cellular Therapy Now Available
This key resource is derived for a distinct readership in laboratories from the AABB Technical Manual, 18th edition. Methods covered include collection and processing of hematopoietic stem cells (HSCT), umbilical cord blood, blood, marrow and tissue-derive non HSCT sources for use in cell-based therapies. Available now in the AABB Marketplace.
Advertisement
 
Industry News & Practice
Infinity enters collaborative deals to develop blood cancer drug
Infinity Pharmaceuticals has partnered with AbbVie and Roche to develop and commercialize duvelisib as a treatment for hematologic cancers. The agreement with Roche covers a series of trials for duvelisib in combination with obinutuzumab. The AbbVie deal includes an upfront payment of $275 million and up to $530 million in possible milestone payments. OncLive (9/23)
Share: LinkedInTwitterFacebookGoogle+Email
NIH supports institute's development of vaccines against staph infections
The National Institutes of Health has given a four-year, $1.3 million grant to the Los Angeles Biomedical Research Institute to support the development of vaccines against health care-associated infections. The study team is developing vaccines against Candida and methicillin-resistant Staphylococcus aureus. BeckersHospitalReview.com (9/23)
Share: LinkedInTwitterFacebookGoogle+Email
The Buzz
Register for the NBF Golf Tournament and Run for Research Today
Enjoy what Philadelphia has to offer while networking with colleagues. The National Blood Foundation (NBF) is accepting registrations for the 18th Annual Golf Tournament and Challenge Cup and the 16th Annual 5K Run for Research/1-Mile Walk. Your participation supports continued medical research that benefits patients and donors. Register today.
 
Government & Regulatory
FDA fast-tracks MedImmune's pneumonia drug candidate
AstraZeneca unit MedImmune's experimental monoclonal antibody drug MEDI3902 secured fast-track designation from the FDA as a preventive treatment for nosocomial pneumonia due to Pseudomonas aeruginosa. The drug, which combines three action mechanisms to attack P. aeruginosa, is set to enter early-stage trials. PharmaTimes (U.K.) (9/23)
Share: LinkedInTwitterFacebookGoogle+Email
NIH takes steps to correct sex bias in clinical trials
The National Institutes of Health is awarding $10 million to supplement ongoing research at hospitals and universities in an effort to better understand how medical conditions and treatments manifest differently in men and women. The move seeks to end a long-standing tendency in preclinical research to favor male cell cultures and male animals. Reuters (9/23)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
AABB seeks presenters for Annual Meeting Research and Progress sessions
AABB is seeking presenters to help lead discussions as part of the Research and Progress sessions during the 2014 AABB Annual Meeting. The 90-minute sessions are designed to encourage discussion on issues of interest to the transfusion and cellular therapies communities. This year's RAP sessions will focus on cellular therapies, new global viral pathogens, changes in red blood cell storage and transfusion triggers in premature infants. AABB members who would like to participate should e-mail AABB by Friday, Oct. 3, and include the title of the RAP session of interest in the subject line of the message.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
Click here to view more job listings.
 
SmartQuote
True happiness is ... to enjoy the present, without anxious dependence upon the future."
-- Seneca,
Roman philosopher and playwright
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tom Parks
Managing Editor:  Amanda Horn
Advertising Manager:  Annette Bacchus
  M: 240.333.6604
 
 

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information